Atara Biotherapeutics Price Target Announced at $25.00/Share by Rodman & Renshaw

Dow Jones12/20 21:11

Atara Biotherapeutics Analyst Ratings

Benzinga12/20 20:59

Kyverna Therapeutics Picks Former Atara Bio, Kite Executives for Leadership Roles

MT Newswires12/14 05:50

Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive...

PR Newswire12/08 01:33

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Businesswire11/28 05:01

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Businesswire11/14 05:01